NVP-025

N/A

Report date: 2026/03/30 17:02:26

Base Information

Drug NameNVP-025
Drug Alias Namecyclophilin D inhibitors (NeuroVive/Karolinska Institutet)sanglifehrin derivatives (Abliva AB/Karolinska Institutet)Sangamides (NeuroVive/Karolinska Institutet)sanglifehrin derivatives (NeuroVive/Karolinska Institutet)NVP-025
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclophilin D inhibitors
TargetsCyclophilin D
Therapy Area/IndicationsMitochondrial Myopathies
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySweden
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAbliva AB
China Registration ClassN/A

Develop Information

Active CompaniesAbliva ABKarolinska Institutet
Inactive CompaniesN/A
Active IndicationsMitochondrial Myopathies
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A